Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
about
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trialsRole of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.Novel systemic therapies for the treatment of psoriasis.Targeting IL-17 with ixekizumab in patients with psoriasis.Secukinumab (AIN-457) for the treatment of Psoriasis.Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.Ixekizumab: First Global Approval.The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis.Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.Erythrodermic psoriasis: current and future role of biologicals.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).[Pustular psoriasis].Interleukin-17 blockade in generalized pustular psoriasis - new hope for severely ill patients.Old and New Biological Therapies for Psoriasis.Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.IL-17 Responses Are the Dominant Inflammatory Signal Linking Inverse, Erythrodermic, and Chronic Plaque Psoriasis.Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.Erythrodermic psoriasis: pathophysiology and current treatment perspectives.Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.
P2860
Q33626095-474734C1-89D7-45B4-9CE2-B1D0512D33ECQ35643453-D9D79D3D-BD82-43B9-9DA1-9684BDB32D1EQ37712237-9B0D6800-0404-4F06-95FE-7596A85A9503Q38628193-6A603339-C735-489D-BF46-8683298949A1Q38633741-A1E8D7EC-A207-4528-B2A9-2828221FB92FQ38662868-D14CD780-7E45-4396-8EB0-087550D43D96Q38663614-4F93A783-D3FD-4E51-86F7-D270354147F9Q38669060-A92488DF-CAD9-4ACE-994D-5FF61F74BE9EQ38813174-69D5EAF0-CA92-4F19-B811-1F8A53D41AFBQ38840275-EE89D252-3FAB-4E1F-8F9E-17DFD995B631Q38895147-4A27CC62-7617-468B-B4B1-A116FF90EC2DQ38961129-0E5A4CAC-F3FF-4183-9E24-0355D4488450Q38969026-2CD5AD17-CF2C-4220-96FB-F60B833CA83CQ38990571-6213EA89-2C57-4C7C-BDC6-8A14C460A472Q39031386-9E16C326-7031-44C8-A6E4-6C4834BA93AAQ39264020-E14A76A7-AAAF-46C5-B74D-421AA0A27145Q40164166-AEACE1C0-B7A9-4BF8-9136-D2090058821EQ40653524-335BB71B-44A2-4FCD-B8AF-3BA9DAB0EBBAQ47583278-BEC261AB-4414-4962-8F6E-934C559FCEF4Q47859049-D36485F0-4AE5-4C4E-AD29-547B3EC00F34Q48170767-7435EBB7-287B-4C69-9A15-0F69717CBCB3Q50067451-4A54E049-EFAD-4349-9CB9-D2E81972B1E8Q53756627-70DE556C-4396-456B-8DF2-ADEBD407B3B1Q55020325-CAE52B61-0B29-4906-BF31-35C4D214DA27Q55101112-378BE16E-5348-499F-A13D-60653E26C64D
P2860
Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Efficacy and safety of open-la ...... eneralized pustular psoriasis.
@en
type
label
Efficacy and safety of open-la ...... eneralized pustular psoriasis.
@en
prefLabel
Efficacy and safety of open-la ...... eneralized pustular psoriasis.
@en
P2093
P2860
P356
P1476
Efficacy and safety of open-la ...... eneralized pustular psoriasis.
@en
P2093
H Nakagawa
M Heffernan
P-Y Berclaz
Y Morisaki
P2860
P304
P356
10.1111/JDV.12773
P577
2014-10-30T00:00:00Z